JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA

Key Points

• JPMorgan Chase increased its stake in Zevra by 1,458.8% in Q3, adding 410,823 shares to hold 438,984 shares (about 0.78% of the company) valued at roughly $4.18 million.
• Company insiders have been net sellers: CEO Neil McFarlane sold 91,000 shares (≈$853,580) and insiders sold a total of 114,158 shares worth about $1.06 million over the last 90 days, leaving insiders with a 2.40% ownership stake.
• Analysts show a consensus of a "Moderate Buy" with an average price target of $23.00 (seven Buy, two Hold), while the stock trades near $9.40 with a market cap of about $551.9 million and a P/E of 7.07.

JPMorgan Chase & Co. lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 1,458.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 438,984 shares of the company's stock after acquiring an additional 410,823 shares during the period. JPMorgan Chase & Co. owned approximately 0.78% of Zevra Therapeutics worth $4,175,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Royce & Associates LP bought a new position in Zevra Therapeutics during the third quarter worth about $6,574,000. Kingdon Capital Management L.L.C. grew its stake in shares of Zevra Therapeutics by 44.4% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 650,000 shares of the company's stock valued at $6,182,000 after purchasing an additional 200,000 shares during the period. Schroder Investment Management Group bought a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at approximately $2,779,000. Cantor Fitzgerald L. P. raised its holdings in shares of Zevra Therapeutics by 487.9% in the 3rd quarter. Cantor Fitzgerald L. P. now owns 117,576 shares of the company's stock worth $1,118,000 after buying an additional 97,575 shares in the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter worth approximately $113,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Neil F. Mcfarlane sold 91,000 shares of Zevra Therapeutics stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $9.38, for a total value of $853,580.00. Following the completion of the transaction, the chief executive officer directly owned 364,350 shares of the company's stock, valued at $3,417,603. The trade was a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Adrian W. Quartel sold 4,533 shares of the company's stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $8.83, for a total transaction of $40,026.39. Following the transaction, the insider owned 9,723 shares in the company, valued at approximately $85,854.09. This trade represents a 31.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 114,158 shares of company stock worth $1,062,878 over the last ninety days. Company insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Wall Street Zen lowered Zevra Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 14th. BTIG Research assumed coverage on Zevra Therapeutics in a research note on Monday, March 16th. They set a "buy" rating and a $23.00 price objective for the company. Weiss Ratings raised Zevra Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a report on Tuesday, March 10th. Guggenheim set a $23.00 target price on shares of Zevra Therapeutics and gave the stock a "buy" rating in a report on Tuesday, March 10th. Finally, HC Wainwright set a $26.00 target price on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Zevra Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $23.00.

Zevra Therapeutics Price Performance

NASDAQ ZVRA opened at $9.40 on Friday. The firm has a market cap of $551.87 million, a PE ratio of 7.07 and a beta of 0.89. Zevra Therapeutics, Inc. has a one year low of $6.19 and a one year high of $13.16. The stock's 50 day simple moving average is $9.11 and its 200 day simple moving average is $9.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.68 and a quick ratio of 5.63.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.